Novel Treatment of Residual Peri-MitraClip Regurgitation With an Amplatzer Vascular Plug II

Published on Sep 12, 2016in Jacc-cardiovascular Interventions8.432
· DOI :10.1016/J.JCIN.2016.06.016
Mohamad Alkhouli24
Estimated H-index: 24
(Mayo Clinic),
Abdallah El Sabbagh13
Estimated H-index: 13
(Mayo Clinic)
+ 3 AuthorsMackram F. Eleid33
Estimated H-index: 33
(Mayo Clinic)
Sources
Abstract
Significant residual mitral regurgitation (MR) may persist after MitraClip (Abbott Vascular, Santa Clara, California) implantation in up to 7% of patients with degenerative MR [(1)][1]. Treatment of the residual MR with an adjacent MitraClip may not be feasible, because of commissural location,
References2
Newest
#1Maurizio TaramassoH-Index: 33
#2Michel ZuberH-Index: 26
Last. Francesco MaisanoH-Index: 84
view all 6 authors...
Aims: We present here the first-in-man case report of a patient with a significant residual "intra-clip" jet treated by the implantation of an AMPLATZER Vascular Plug II. Methods and results: A 64-year-old gentleman came to our attention for mitral regurgitation (MR) recurrence four years after transcatheter mitral repair with MitraClip. After the implantation of two further MitraClips, residual intra-clip MR was present, without room for a further clip. An AMPLATZER Vascular Plug II was success...
9 CitationsSource
#1Paul Sorajja (Abbott Northwestern Hospital)H-Index: 6
#1Paul Sorajja (Abbott Northwestern Hospital)H-Index: 24
Last. Gorav Ailawadi (UVA: University of Virginia)H-Index: 64
view all 13 authors...
Abstract Background Transcatheter mitral valve (MV) repair with the MitraClip received approval in 2013 for the treatment of prohibitive-risk patients with primary mitral regurgitation (MR). Objectives The aim of this study was to report the initial U.S. commercial experience with transcatheter MV repair. Methods Data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry on patients commercially treated with this percutaneous mitral valve repai...
123 CitationsSource
Cited By3
Newest
Abstract Mitral valve regurgitation (MR) affects approximately 4 million people in the United States alone, increasing in prevalence with age. Approved by the Food and Drug Administration (FDA) in October 2013, percutaneous edge-to-edge transcatheter mitral valve repair (also known as the MitraClip system) has been used in over 40,000 patients globally. Additionally, there is keen interest and early exploration into the use of MitraClip for treatment of severe symptomatic tricuspid regurgitation...
7 CitationsSource
Implantation of an Amplatzer Closure Device (St. Jude Medical, St. Paul, Minnesota) has been successfully used to treat residual mitral regurgitation (MR) after MitraClip (Abbott, Abbott Park, Illinois) implantation in selected situations to obliterate the residual jet. Different types and sizes of
9 CitationsSource
#1Carmelo GrassoH-Index: 16
#2Sergio BuccheriH-Index: 13
Last. Corrado TamburinoH-Index: 85
view all 14 authors...
Percutaneous mitral valve repair (PMVR) with the MitraClip system (Abbott Vascular, Santa Clara, CA, USA) is a valid therapeutic option for patients with severe mitral regurgitation (MR) deemed to be
3 CitationsSource